[Effects of carvedilol (beta 1, beta 2, alpha 1 bloker) on refractory congestive heart failure]

E A Bocchi1, F Bacal, G Bellotti

  • 1Instituto do Coração do Hospital das Clínicas, FMUSP.

Insights

Carvedilol improved heart function and reduced symptoms in patients with severe heart failure. This beta-blocker offers a potential treatment option for refractory heart failure when tolerated.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Severe heart failure management remains challenging.
  • The efficacy of beta-blockers in refractory heart failure is not fully understood.

Purpose of the Study:

  • To investigate the effects of carvedilol on symptoms, functional class, and left ventricular function in patients with refractory heart failure.

Main Methods:

  • A study involving 21 patients with refractory heart failure (NYHA class III/IV).
  • Progressive dosage increase of carvedilol, starting at 6.25 mg.
  • Evaluations included clinical assessment, ECG, echocardiogram, and MUGA scan after approximately 196 days.

Main Results:

  • Carvedilol was well-tolerated in 76% of patients.
  • Significant improvements observed in functional class, with most patients moving to class I or II.
  • Key cardiac improvements included decreased heart rate, reduced left ventricular end-diastolic diameter, and increased left ventricular ejection fraction.

Conclusions:

  • Carvedilol demonstrates potential benefits in improving cardiac function and remodeling in refractory heart failure.
  • It may serve as a viable treatment option for patients who tolerate the medication.
  • Further research is needed to confirm long-term effects in this patient population.
Abstract

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...